No profile data available.
Biogen Inc. (BIIB) is a healthcare company in the brain and nerve treatment drugs industry, based in Cambridge, United States, with about 7,500 full-time employees.
In Q2 2026 (the quarter ended June 30, 2026) revenue was $2.74 billion. United States was its largest region in fiscal year 2025, with 59% of revenue. Its market capitalization was $33.35 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
United States: 59% of revenue by region in fiscal year 2025, followed by Europe (19%).
$33.35 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include argenx SE (ARGX), Neurocrine Biosciences, Inc. (NBIX), Jazz Pharmaceuticals plc (JAZZ), Axsome Therapeutics, Inc. (AXSM).